Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606892 · ClinicalTrials.gov registry record · NA
Varenicline and Nicotine Interactions in Humans (VA)
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 37
- Enrollment target
NCT00606892 is a NA study that has completed, run by Yale University. The registered enrollment target is 37 participants.
The verdict
NCT00606892, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 37 participants
- Enrollment target
Study Summary
To examine the effects of varenicline on the subjective, physiological and cognitive responses to intravenous nicotine. Varenicline is a partial nicotine agonist and it is approved as a treatment for smoking cessation. We predict that varenicline treatment will modify subjective, physiological and cognitive responses to IV nicotine.
Interventions
- DRUG Placebo
- DRUG Varenicline
- DRUG IV Nic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00606892
The ClinicalTrials.gov registry entry for NCT00606892 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00606892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00606892 about?
NCT00606892 is a clinical study titled "Varenicline and Nicotine Interactions in Humans (VA)". To examine the effects of varenicline on the subjective, physiological and cognitive responses to intravenous nicotine. Varenicline is a partial nicotine agonist and it is approved as a treatment for smoking cessation. We predict that varenicline treatment will modify subjective, physiological and c...
What is the current status of trial NCT00606892?
This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2007-08. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00606892?
The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG), IV Nic (DRUG).
Who is sponsoring clinical trial NCT00606892?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.